RxDoctor Payments DataLook up a doctor →

Leigh van Devender, APRN

Gerontology · Oxford, MSNPI 1376198192

Payments from drug & device makers

$16,270in general payments, 2019–2025

Across 884 payments — averaging $18.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$4K
  • AbbVie$4K
  • Johnson & Johnson$1K
  • Novartis$1K
  • UCB, Inc.$1K
  • Boehringer Ingelheim$966
  • plus $4K from 18 others

What the payments were for

  • Food & beverage$15,98398%
  • Education$2872%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,270 in reported general payments places this provider in the 95th percentile of 66 gerontology providers in Mississippi.

See all gerontology providers in Mississippi

Medicare billing

Part B allowed, 2024
$56,613
Medicare patients
491
Services billed
1,078

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab108$821,166
RinvoqUpadacitinib92$562,236
Enbrel SureclickEtanercept57$399,982
Taltz Autoinjector (2 Pack)Ixekizumab16$211,675
Actemra ActpenTocilizumab56$194,108
Cimzia (2 Pack)Certolizumab Pegol19$123,196
Enbrel MiniEtanercept13$92,368
KevzaraSarilumab19$77,915
Orencia ClickjectAbatacept13$71,849
BenlystaBelimumab20$67,186
ActemraTocilizumab12$27,791
Hydroxychloroquine Sulfate452$17,348
MethotrexateMethotrexate Sodium280$6,726
Leflunomide89$3,332
Mycophenolate Mofetil16$3,205

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$3,602$562,23692 claims
UCB, Inc.Cimzia (2 Pack)$1,104$123,19619 claims
SanofiKevzara$108$77,91519 claims
GSKBenlysta$133$67,18620 claims
Scilex Pharmaceuticals Inc.Colchicine$46$1,69544 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 66 gerontology providers in Mississippi.

Other gerontology in Oxford

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →